316 related articles for article (PubMed ID: 34050699)
1. Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy.
Lee D; Huntoon K; Wang Y; Jiang W; Kim BYS
Adv Mater; 2021 Jul; 33(27):e2007576. PubMed ID: 34050699
[TBL] [Abstract][Full Text] [Related]
2. Exploiting innate immunity for cancer immunotherapy.
Yi M; Li T; Niu M; Mei Q; Zhao B; Chu Q; Dai Z; Wu K
Mol Cancer; 2023 Nov; 22(1):187. PubMed ID: 38008741
[TBL] [Abstract][Full Text] [Related]
3. Harnessing innate immunity in cancer therapy.
Demaria O; Cornen S; Daëron M; Morel Y; Medzhitov R; Vivier E
Nature; 2019 Oct; 574(7776):45-56. PubMed ID: 31578484
[TBL] [Abstract][Full Text] [Related]
4. Innate Immunity in Cancer Biology and Therapy.
Zhang Y; Xue W; Xu C; Nan Y; Mei S; Ju D; Wang S; Zhang X
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37510993
[TBL] [Abstract][Full Text] [Related]
5. Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy.
Chen S; Lai SWT; Brown CE; Feng M
Front Immunol; 2021; 12():635173. PubMed ID: 33790906
[TBL] [Abstract][Full Text] [Related]
6. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
7. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
Ginefra P; Lorusso G; Vannini N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
[TBL] [Abstract][Full Text] [Related]
8. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
9. Harnessing biomaterial architecture to drive anticancer innate immunity.
Davis MA; Cho E; Teplensky MH
J Mater Chem B; 2023 Nov; 11(46):10982-11005. PubMed ID: 37955201
[TBL] [Abstract][Full Text] [Related]
10. Advanced Biomaterials with Intrinsic Immunomodulation Effects for Cancer Immunotherapy.
Chen W; Li C; Jiang X
Small Methods; 2023 May; 7(5):e2201404. PubMed ID: 36811240
[TBL] [Abstract][Full Text] [Related]
11. Boosting Checkpoint Immunotherapy with Biomaterials.
Liu L; Pan Y; Zhao C; Huang P; Chen X; Rao L
ACS Nano; 2023 Feb; 17(4):3225-3258. PubMed ID: 36746639
[TBL] [Abstract][Full Text] [Related]
12. Immunoengineering with biomaterials for enhanced cancer immunotherapy.
Xie YQ; Wei L; Tang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Jul; 10(4):e1506. PubMed ID: 29333729
[TBL] [Abstract][Full Text] [Related]
13. Emerging immunological strategies: recent advances and future directions.
Zhao H; Luo F; Xue J; Li S; Xu RH
Front Med; 2021 Dec; 15(6):805-828. PubMed ID: 34874513
[TBL] [Abstract][Full Text] [Related]
14. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
[TBL] [Abstract][Full Text] [Related]
15. Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.
Ruan S; Huang Y; He M; Gao H
Adv Sci (Weinh); 2022 May; 9(16):e2200027. PubMed ID: 35343112
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibodies for immune cell retargeting against cancer.
Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
[TBL] [Abstract][Full Text] [Related]
17. Targeting intracellular and extracellular receptors with nano-to-macroscale biomaterials to activate immune cells.
Wang B; Cui H; Kiessling F; Lammers T; Baumjohann D; Shi Y
J Control Release; 2023 May; 357():52-66. PubMed ID: 36958399
[TBL] [Abstract][Full Text] [Related]
18. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
19. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
20. Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.
Uher O; Caisova V; Hansen P; Kopecky J; Chmelar J; Zhuang Z; Zenka J; Pacak K
Semin Oncol; 2019; 46(4-5):385-392. PubMed ID: 31739997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
